Apr. 9 at 12:28 PM
$CRVO Earlier this week, our CEO Dr. John Alam participated on a panel at the Lewy Body Dementia Association annual meeting with other industry leaders discussing the use of biomarkers in detecting and monitoring dementia with Lewy bodies (#DLB).
He pointed out the need for distinct blood and imaging biomarkers to identify and assess DLB relative to other dementias, including Alzheimer’s disease, as DLB is uniquely driven by synaptic dysfunction. We’ve explored the use of relevant biomarkers, such as glial fibrillary acidic protein (GFAP) and plasma pTau181, in our prior clinical trials of neflamapimod, and will build on what we’ve learned in our planned Phase 3 trial, which will start later this year.
#Biomarkers #neflamapimod #LBDA
